Tourmaline Bio, Inc.
TRML · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.00 | -0.00 | 18,393.72 |
| FCF Yield | -15.03% | -22.64% | -5.56% | -2.55% |
| EV / EBITDA | -5.39 | 0.35 | -10.14 | -35.07 |
| Quality | ||||
| ROIC | -29.86% | -22.07% | -244.46% | -983.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 0.67 | 0.33 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -174.63% | -144.12% | 72.83% | -106.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | 3.09 | 0.39 | 0.39 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -145.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -33,533.21 | -11,845.91 | -24,394.17 | -113.66 |